A high-dose (HD) chemotherapy scheme was designed for the collection of large numbers of peripheral blood progenitor cells (PBPC) in lymphoma patients who were candidates for myeloablative therapy with autograft. The scheme included the sequential administration of HD cyclophosphamide (CY) (7 g/m 2 ) and HD ara-C (2 g/m 2 twice a day for 6 consecutive days), followed by final consolidation with PBPC autograft. PBPC harvests were scheduled following both HD CY and HD ara-C. To minimize hematologic toxicity, small aliquots of PBPC (р3 ؋ 10 6 CD34 + cells/kg) collected following HD CY were reinfused following HD ara-C. The treatment was delivered to 112 patients (median age: 43 years) with lymphoid malignancies (107 non-Hodgkin's lymphoma, four Hodgkin's lymphoma, one amyloidosis); 75 patients were at disease onset, whereas 37 had relapsed or were refractory after first-line conventional therapy. C respectively (P = NS). Thus, the scheme allowed sufficient PBPC collections for autografting in low mobilizer patients; in addition, the scheme could be considered whenever extensive chemotherapy debulking is needed prior to PBPC collection.
High-dose (HD) chemotherapy with autograft is widely used in the management of chemosensitive tumors, especially lymphomas, where it is now the most frequently employed treatment for patients younger than 65 years at relapse. [1] [2] [3] [4] [5] [6] [7] There is also recent evidence of its potential efficacy as a first-line approach in high-risk patients. [8] [9] [10] [11] [12] [13] [14] Indeed, clinical applicability of HD chemotherapy with autograft has been greatly amplified by the use of peripheral blood progenitor cells (PBPC), whose administration is simple and feasible, and results in lower toxicity and better cost-effectiveness than bone marrow transplantation. [15] [16] [17] A prerequisite for the success of PBPC-based procedures is effective mobilization to collect sufficient numbers of hematopoietic progenitors for rapid and stable engraftment. [18] [19] [20] Mobilization schedules are now well standardized and good harvests are easily obtained in most cases. Even so, it may be difficult to gather the numbers required for engraftment, especially in patients with extensive bone marrow disease or prolonged previous treatments. [21] [22] [23] [24] [25] Moreover, a small fraction of non-heavily pretreated patients are for some obscure reason unable to mobilize adequate amounts, even under what are at present the best-known conditions. 26 Good mobilization is obtained by combining different chemotherapy schedules with hemopoietic growth factors. The most effective combination is HD chemotherapy and G-CSF. 25, 27 Satisfactory, though less substantial mobilization is also provided by G-CSF alone. [28] [29] [30] The inclusion of chemotherapy also offers the by no means negligible advantage of effective in vivo purging prior to PBPC collection. Repeated chemotherapy courses might reduce the risk Bone Marrow Transplantation of tumor cell contamination of the harvested PBPC. [31] [32] [33] However, they may severely hamper mobilization, especially if given at short intervals. 34, 35 This paper describes the evaluation of an innovative mobilizing procedure consisting of the administration of HD cyclophosphamide (CY) followed by HD ara-C, two drugs with a high mobilizing activity. Post-CY harvested PBPC were reinfused following HD ara-C to reduce hematological toxicity. Mobilization was both feasible and surprisingly good even after the second aggressive treatment, while patients unable to produce enough PBPC following HD CY achieved good or at least sufficient mobilization and harvests were restored following HD araC given with PBPC support.
Patients and methods

Patient characteristics
Between 1997 and 1999, 112 patients aged 18-60 years with poor-prognosis malignant lymphoproliferative disease (107 non-Hodgkin's lymphoma, four relapsed Hodgkin's lymphoma, one amyloidosis) underwent the intensive sequential HD chemotherapy and PBPC autograft program detailed below. All patients gave written informed consent before starting the program. Study protocols, including the sequence HD CY → HD ara-C along with PBPC collections and reinfusions, had been approved by our institutional Ethics Committee. Seventy-five patients were at disease onset and 37 had relapsed disease or were refractory following one line of conventional chemotherapy. The main patient characteristics are summarized in Table 1 .
Treatment plan
The program consisted of three phases: (1) debulking with conventional dose chemotherapy; (2) an HD phase with double PBPC collection and reinfusion; (3) a myeloablative phase with PBPC autograft. Debulking was done with three courses of a modified APO regimen: 36 three total doxorubicin administrations at 75 mg/m 2 plus vincristin 1.4 mg/m 2 (maximal total dose 2 mg), both given as bolus i.v. infusions on days +1, +15, +22, and prednisone (1 mg/kg) given daily orally, starting day +1 to day +22, along with , infused in 2 h starting 16 h after etoposide). Each course was started when the ANC was Ͼ1000/l and platelets were Ͼ100 000/l, and was followed by support with s.c. G-CSF (5 g/kg/day starting the day after chemotherapy and continued until ANC recovery or PBPC harvest completion). PBPC were harvested at the time of maximal mobilization following both HD CY and HD ara-C. To predict optimal timing of leukapheresis, circulating CD34 + cells and blood cell counts were evaluated daily starting from day +9 after chemotherapy until the end of harvesting. An aliquot of PBPC collected following CY (р3 ϫ 10 6
CD34
+ cells/kg) was reinfused the day immediately following the last dose of HD ara-C to minimize hematological toxicity. The PBPC collection and reinfusion scheme is shown in Figure 1 . Patients at risk for meningeal disease also received HD methotrexate (MTX) (8 g/m 2 , given over 8 h, and followed by folinic acid rescue) prior to VP16 and cisplatin. The myeloablative phase with PBPC autografting included a conditioning regimen with HD mitoxantrone (MITO) and HD L-PAM given i.v. at 60 mg/m 2 and 180 mg/m 2 on day Ϫ5 and day Ϫ2, respectively, and PBPC were reinfused 2 days later, as detailed elsewhere. 37 To accelerate hemopoietic recovery, G-CSF was given i.v. over 1 h at 5 g/kg/day starting on day +1 following autograft until ANC reached 500/l on 2 consecutive days. 38 
PBPC evaluation and collection
Blood samples were analyzed for the presence of circulating progenitors from day +9-+10 following HD CY and HD ara-C until ANC recovery or completion of harvesting. Circulating and harvested progenitors were determined by evaluation of CD34 + cells. 25 The CD34 assay was performed on whole blood as well as on leukapheresis specimens by cytofluorometric analysis using the monoclonal antibody anti-CD34 HPCA-2 (Becton Dickinson, San Jose, CA, USA). Briefly,100 l of heparinized whole blood or 2-3 ϫ 10 6 cells from leukapheresis collections were incubated with 10 l of anti-CD34 PE for 30 min at room temperature in the dark. Red cells were removed by hypotonic lysis with NH 4 Cl buffer for 15 min in the dark, followed by two washes with PBS supplemented with 1% BSA and 0.1% sodium azide. Cells were then resuspended in PBS and analyzed with a FACSCalibur cytofluorimeter (Becton Dickinson), equipped with a filter set for FITC-PE dualcolor fluorescence. Data acquisition and analysis were performed with CELLQuest software and each measurement included at least 40 000 events. Dead cells were excluded on the basis of forward and side-scatter analysis. The frequency of CD34
+ cells was calculated as the percentage of all viable cells. The number of circulating CD34 + cells was obtained by multiplying this percentage by the total number of leukocytes in 1 l of blood; the total number of CD34 + cells (ϫ10 6 /kg) in leukapheresis yields was calculated by multiplying CD34
+ percentage by the total number of leukocytes collected and dividing by body weight. Myeloid progenitors were also evaluated as in vitro clonogenic cells (CFU-GM) in 55 patients. 25 CFU-GM were estimated in leukapheresis products by plating in semisolid medium 1, 10 and 100 l of the buffy coat obtained from the leukapheresis cell suspension with no additional cell separation to avoid progenitor cell enrichment. The total number of CFU-GM collected (ϫ10 4 /kg) was determined by multiplying their frequency per ml by the total volume of cryopreserved cell suspension and dividing by body weight.
Peripheral blood buffy-coat cells were collected when the WBC count was at least 1000/l and PB CD34
+ cells Ͼ20/l. Leukapheresis was performed with continuousflow blood cell separators (Cobe-Spectra or Fresenius). From 7 to 13 l blood (median 8.9 l) were processed in each procedure.
Statistical analysis
Differences in the means of continuous measurements were compared in groups of patients by the Mann-Whitney U test with P Ͻ 0.05 as the significance cut-off. All P values presented are two-sided.
Results
High and low mobilizers
A cut-off of 20 CD34
+ cells/l was arbitrarily chosen to define high-and low-mobilizer groups as a function of their PBPC peak on the day of maximal mobilization. Several previous observations have shown that poor PBPC collections are to be expected below this level. 26, 39, 40 Ninety-three patients (83%) were classed as high mobilizers and 19 (17%) as low mobilizers.
Four low mobilizers were at disease onset and had normal bone marrow. The remainder had either refractory/relapsed disease (six patients), bone marrow involvement with lymphoma cells (two patients) or both (seven patients).
PBPC mobilization in low mobilizers
All 19 low mobilizers received HD ara-C, with reinfusion of low amounts of autologous PBPC (0. Figure 2 compare the extent of mobilization expressed as circulating CD34
+ cells/l peak value following HD CY and HD ara-C in this group. The median peak values of 10 (range 1-20) and 37.3 (range 3.5-277) following HD CY and HD ara-C were significantly different (P = 0.001). + cells/kg are plotted as box plots. A value of 0 was assigned to those patients not undergoing leukapheresis due to very poor mobilization, following HD CY (three patients) and HD ara-C (two patients).
require a significantly higher number of harvest procedures (see Table 2 ).
The individual information on PBPC mobilization and harvesting in the 19 poor mobilizer patients according to their main clinical features is reported in Table 3 .
Long-term engraftment in low mobilizers
Fifteen low mobilizer patients underwent autograft with reinfusion of their PBPC collected following HD ara-C. Engraftment took place in every case. As shown in Table  4 , a satisfying WBC value was observed after 2 weeks and hematopoietic reconstitution was also durable, as confirmed by the 2-month and 6-month values. Platelet recovery also took place, albeit slowly. The median platelet count at discharge, about 2 weeks after autograft, was 39 000/l, but a Among 19 low mobilizer patients, three and two patients did not undergo leukapheresis following HD CY and HD ara-C, respectively, due to extremely poor mobilization. b CFU-GM were evaluated in 14 low mobilizer and 41 high mobilizer patients. c 93 patients displayed high mobilization and underwent PBPC harvest following HD CY; 88 of them received HD ara-C; among these latter, 13 did not undergo PBPC harvest due to very poor mobilization (eight patients) or to extremely high collections following the previous HD CY course then rose to 84 000 and 102 000/l at 3 and 6 months after autograft. Median hemoglobin values remained lower than normal, but no patient was transfusion-dependent following post-graft discharge.
PBPC mobilization in high mobilizers
Treatment was discontinued following HD CY in five high mobilizers due to disease progression. Thus, HD ara-C was delivered to 88 patients. Of these, 79 (90%) displayed high mobilization and yielded high PBPC numbers following both HD CY and HD ara-C. Box plots in Figure 4 show the extent of mobilization expressed as peak values of circulating CD34 + cells/l following HD CY and HD ara-C. Median peak values were 192 following HD CY (range 24-1178) and 172 following HD ara-C (range 0-1342). This difference was not significant (P = 0.45).
There were almost no differences in the harvest extent following HD CY and HD ara-C. The median totals were 17. Table 2 , there was also no difference in terms of PBPC yield per harvest procedure or in the number of procedures performed.
Discussion
This paper describes a novel strategy for the collection of PBPC in patients who were candidates for consolidation therapy with autograft. The program includes PBPC collections following each of two consecutive intensive courses, the first with HD CY and the second with HD ara-C, both supplemented with G-CSF. To reduce hematologic toxicity, small aliquots of PBPC were reinfused after HD ara-C. The program was carried out in a group of lymphoma patients. Two-thirds of them were at disease onset, the remainder in 729  Table 3 Individual information of the 19 poor mobilizer patients progression after one line of conventional therapy. Most patients mobilized and yielded large numbers of PBPC following HD ara-C, including those displaying poor mobilization following HD CY. Thus, the schedule allows collection of sufficient PBPC in patients unable to give good harvests following a potent mobilizing course, such as HD CY. In addition, the schedule makes it feasible to collect PBPC following repeated HD chemotherapy courses: this could be useful whenever an extensive tumor debulking is needed prior to PBPC harvesting.
This series of 112 patients is large enough to allow conclusions to be drawn with regard to the program's feasibility and efficacy in terms of PBPC mobilization and harvest. All patients were younger than 60 years, presented with advanced stage disease and had not been heavily pretreated. They thus possessed the features usually accepted for enrolment in intensive chemotherapy approaches with autograft. 2, 3 Two groups of patients were distinguished according to the extent of their progenitor mobilization following HD CY + G-CSF. Most showed high levels of circulating progenitors and were defined as 'high mobilizers', whereas about 17% displayed very low peripheral blood progenitor levels and were defined as 'low mobilizers'. The arbitrary 20 CD34
+ cells/l cut-off used for this distinction was chosen because previous studies have shown that levels below 20/l predict very poor harvests, usually insufficient for engraftment. 26, 39, 40 Those of the 19 low mobilizers, in fact, were far below the safe autograft threshold, while all the high mobilizers had large progenitor cell collections with a median of only one leukapheresis. Both the number of circulating progenitors and PBPC harvests following HD CY + G-CSF thus distinguished two groups of patients with remarkably different mobilization capacity.
New cytokines or combinations of old and new ones have recently been proposed as effective tools for mobilization. [41] [42] [43] [44] [45] [46] However, HD CY + G-CSF is still one of the most effective mobilizing procedures, at least in nonheavily pretreated patients. 15, 25, 27, 47, 48 In the present series, 83% of patients displayed massive progenitor mobilization with easy harvest of large quantities of PBPC for autografting. Since HD CY also has a potent anti-tumor activity, HD CY + G-CSF remains one of the most suitable treatments for lymphoma patients enrolled in chemotherapy programs that include PBPC autograft.
The poor mobilization displayed by some patients after HD CY + G-CSF was attributable to progressive disease following a previous induction treatment, bone marrow involvement or both. [21] [22] [23] [24] [25] 46, 49 Another four patients with normal bone marrow and no previous treatments unexpectedly did not mobilize at all. When many patients are analyzed, in fact, one cannot rule out the presence of a minority unable for some obscure reason to release progenitor cells into peripheral blood even under optimal mobilization conditions. 26 Most of these poor mobilizers restored good or at least sufficient mobilization and harvests following HD ara-C given with PBPC support. No other procedures have proved capable of turning a 'poor' mobilizer into a 'good' one. 50, 51 The possibility of restoring good harvests in poor mobilizers proves the efficacy of our approach.
Extensive tumor debulking prior to PBPC collection may be desirable to reduce the risk of tumor cell contamination in the harvest products for patients presenting with advanced disease and/or bone marrow involvement. Contamination has often been detected in PBPC collections of patients with low-grade lymphoma [31] [32] [33] and molecularly detectable lymphoma cells have been encountered in approximately 40% PBPC harvests from patients with diffuse large cell subtype, even in the absence of overt bone marrow involvement. 52 On the other hand, a marked reduction or the complete absence of contaminating tumor cells has been reported when collections are scheduled following repeated HD chemotherapy courses. 53, 54 This implies a sort of chemotherapy-mediated 'in vivo purging' effect. Thus, our schedule with HD CY/HD ara-C may provide a potent 'in vivo purging' effect and it might be particularly suitable for patients with BM involvement. Furthermore, a reduced marrow contamination might have had a positive influence on PBPC mobilization, at least in those poor mobilizers presenting with BM involvement.
Beside HD CY, several other drugs are able to induce good PBPC mobilization, including HD VP16, as reported by our group and by others. [55] [56] [57] However, previous reports have shown that repeated chemotherapy courses, especially if given at short intervals, may severely hamper mobilization. 34 In particular, low mobilization has been observed after HD VP16 when delivered shortly after HD CY. 35 PBPC collections are only feasible if the mobilizing course is delivered after an adequate chemotherapy-free interval from a previous cytotoxic treatment. 58, 59 Elicitation of an adequate PBPC mobilization with a shortly spaced HD ara-C course was included in the scheme because high doses of ara-C display a potent mobilizing effect. 21, 47, 60, 61 Small numbers of autologous PBPC reinfused after HD ara-C may have positively influenced progenitor mobilization. We can not yet determine whether this mobilization was induced by ara-C, by the reinfused PBPC or both. The schedule was in any event highly effective in terms of quantity of PBPC collected and only a few good mobilizer patients did not show adequate mobilization following ara-C. The addition of anti-B cell humanized antibodies may further improve the program by intensifying the in vivo purging effect prior to PBPC harvesting, as reported by other groups and ourselves. [62] [63] [64] The therapeutic efficacy of the HD CY/HD ara-C schedule supplemented with anti-B cell Rituximab is currently being investigated as salvage therapy for relapsed low-grade lymphoma and first-line treatment for high-risk mantle-cell and diffuse-large B cell lymphomas. 65 High-dose chemotherapy with PBPC autograft is now extensively employed in the management of high-risk lymphoma. Its applicability requires adequate amounts of PBPC for autografting. Several studies suggest that a final autograft phase, following initial debulking with conventional or intensified chemotherapy, may significantly improve the clinical efficacy of salvage programs for relapsed lymphoma patients. 4, 5, 25 In addition, there is evidence that autograft is most effective when performed after maximal cytoreduction. 2 Lastly, the use of adequate numbers of PBPC during autograft significantly reduces both short-and long-term treatment-related toxicities. [16] [17] [18] Our sequential delivery of HD CY, HD ara-C and final myeloablative autograft meets all these requirements: (1) it extends the applicability of PBPPC autograft to patients otherwise ineligible due to initial poor mobilization; (2) it involves a final autograft following intensive debulking; (3) it ensures large numbers of PBPC for rapid and durable engraftment.
